2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era– Tweetorial #2 Pretest

1. How confident are you in the management of patients with multiple sclerosis (MS) in your practice? 

2. What’s your specialty?

3. All of these DMTs have been shown to reduce annualized relapse reductions by at least 50% in phase 3 clinical trial except:

4. In a recent investigation, initiation of a high-efficacy DMT ≤2Y after MS diagnosis was associated with approximately what reduction in risk for progression?

5. Carla is a 35YO female newly diagnosed with RRMS. She has mild MRI disease activity, history of ventricular arrhythmia, and mildly-moderately active. Alleviation of symptoms is a priority and she prefers an oral DMT. Which of the following DMTs would you prescribe?

6. What would you prescribe instead if Carla had been previously diagnosed, had high MRI disease activity, a history of GI sensitivity, & previous inadequate response to teriflunomide?

7. Mitchell is a 40YO male diagnosed with RRMS. He is high risk for disability, very physically active, a full-time general contractor, and has two kids under 10 years old. He has a moderate-to-high level of risk tolerance and prevention of long-term disability is a priority for him. Which of the following DMTs would you prescribe?